Abstract:External exposure concentrations were conventionally employed usedto quantify toxicological effects of chemicals in their risk assessment.However, internal concentrations are more suitable for understandingthe toxicological effects and conducting risk assessment. It is necessaryfor accurate risk assessment of chemicals to predict the internalexposure of chemicals from the external exposure, and to know distributionof chemicals in different target tissues/organs (e.g. liver, kidney)of organisms. Experimental determination can hardly get high-throughputacquisition of target concentrations due to analytical limitationsand expensive cost for in vivo animal tests. Alternatively,physiologically based toxicokinetics (PBTK) models that can quantitativelypredict absorption, distribution, metabolism and excretion (ADME)processes of chemicals in biota are particularly useful. PBTK modelscould be used to predict the target concentrations, and to relatethe environmental exposure concentrations with the target concentrations. Development of PBTK models can be divided into five steps. (1)Specify the general model structure. Portal of entry, target organ,lipophilicity and metabolism of chemicals are basic factors that shouldbe considered. (2) Determine the set of ordinary differential equationsrepresenting the ADME processes of chemicals by the organism. Allof these equations are mass balance equations. (3) Define model parameters,including physiological parameters, partition coefficients, biochemicalrate constants and environment parameters. (4) Solve the ordinarydifferential equations with proper software. (5) Validate the model.Simulation results should be compared with corresponding experimentaldata to evaluate whether the model is accurate enough. Sensitivity,uncertainty and variability analysis should be performed to furtheroptimize the model. Originating as a tool for serving pharmaceutical industry, PBTKmodels are now used in risk assessment of chemicals. PBTK models canalso relate the in vivo toxicity thresholds withthe in vitro toxicity thresholds. The invitro-in vivo extrapolation can facilitate the utilizationof the vast volume of high-throughput in vitro data.Traditional in vivo tests only focus on a limitednumber of the diverse species residing within an ecosystem. PBTK modelscan provide a promising cross-species solution by establishing physiologicallyrelevant models for various species. Besides, classical indicatorsfor hazard assessment such as bioconcentration factors could be re-evaluatedby PBTK models with upgraded accuracy and details. Furthermore, itis possible to simulate the risk of chemicals that exerted on organismsover the entire lifetime of organisms with a sequence of PBTK modelsrepresenting different developmental stages of the species. The combinationof PBTK models and toxicodynamics (TD) models, i.e. PBTK/TD models,can further realize the simulation of the dynamic distribution ofxenobiotics as well as the effects simultaneously. The power of PBTK models intended for ecological risk assessmentof chemicals is yet to be fully exploited. Current PBTK models mainlyapply to chemicals of neutral states. However, the molecular structuresof many organic pollutants have carboxylic, phenolic groups, etc.Thus, these compounds can ionize under environmental pH conditions.A compound with different ionized states could possess different intakepathways. Thus, certain modifications of the mathematical form ofthe PBTK models are necessary. Another major obstacle is that thesophisticated parameters of PBTK models cannot be easily collected.Therefore, schemes for a high-throughput acquisition of the relevantparameters (e.g. quantitative structure-activity relationship models)would be highly useful. Furthermore, PBTK models should be extendedto more species of ecological importance.

PBPK model reporting template for chemical risk assessment applications

Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions

Application of physiologically based toxicokinetics models in risk assessment of chemicals

Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs

Making PBPK models more reproducible in practice

Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report

PBPK modeling and simulation in drug research and development

The Application of a Physiologically Based Toxicokinetic Model in Health Risk Assessment

Nano- and Microplastic PBK modeling in the context of human exposure and risk assessment

Regulatory utility of physiologically-based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report

Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

Recent Progress on Physiologically Based Pharmacokinetic (PBPK) Model: A Review Based on Bibliometrics

Predicting nonlinear relationships between external and internal concentrations with physiologically based pharmacokinetic modeling

The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives

Development of Physiologically Based Toxicokinetic Models for 3-Monochloropropane-1,2-diol and Glycidol.

Physiologically Based Pharmacokinetic Model and Its Applications

Human biomonitoring and toxicokinetics as key building blocks for next generation risk assessment

Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery

Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report

Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration

OECD harmonised template 201: Structuring and reporting mechanistic information to foster the integration of new approach methodologies for hazard and risk assessment of chemicals